Asia-Pacific ECMO Market

The Asia-Pacific ECMO market is expected to grow from US$ 110.85 million in 2022 to US$ 139.19 million by 2028. It is estimated to record a CAGR of 3.9% from 2022 to 2028.

Increasing Survival Rates with ECMO to Offer Opportunities for Asia-Pacific ECMO Market During 2022–2028

The employment of ECMO for treating respiratory failure has been increasing in recent years, as treatments with ECMO show promising survival rates. Further, ECMO is recommended to treat patients suffering from acute respiratory distress syndrome (ADRS), primary graft dysfunction post lung transplant, and trauma to the lungs as it increases the survival rate of patients. Furthermore, ECMO increases the survival rate of patients affected by post-cardiac arrest regimen. A radical shift in adopting westernized lifestyles leads to various cardiac disorders. Thus, key players invest significantly in R&D, which results in improved treatment outcomes with ECMO with an increased survival rate. Therefore, the rising survival rate with ECMO use in various treatments is expected to provide lucrative opportunities for ECMO market in Asia-Pacific during the forecast period.

Asia-Pacific ECMO Market Overview 

Asia-Pacific is the fastest-growing regional ECMO market. China, India, and Japan are major contributors to the Asia-Pacific ECMO market growth in the region. China dominated the market in 2022.  According to an article by the National Center for Biotechnology Information (NCBI) titled "Cardiovascular Health and Diseases in China," Cardiovascular Disease (CVD) accounted for ~47% and 44% of all deaths in rural and urban areas, respectively, in 2019. Two out of every five deaths occur due to CVD, and it is predicted that over 330 million patients suffer from CVD in China. The patients suffering from stroke, heart failure, coronary heart disease, pulmonary heart disease, rheumatic heart disease, atrial fibrillation, lower extremity artery disease, congenital heart disease, and hypertension were found to be 13 million, 11 million, 9 million, 5 million, 4.87 million, 2.50 million, 2 million, 45.30 million, and 245.00 million, respectively. Moreover, according to Statista data, the population aged above 60 years is estimated to grow from 17.4% in 2020 to 30% by 2040. Thus, China is facing the pressures of an aging population and the constant rise in the prevalence of metabolic risk factors. As a result, the CVD burden will continue to increase, setting new requirements for CVD prevention, treatment, and the allocation of medical resources in China. Furthermore, the penetration of international market players in the country is boosting the growth of the ECMO market. In July 2021, Xenios AG, a Fresenius Medical Care company, received approval from the National Medical Products Administration (NMPA) in China for the Xenios console and patient kits for ECMO therapy. Hence, the rising prevalence of CVD, the increasing geriatric population, and advancements by key players are expected to propel the ECMO market in China during the forecast period.

Asia-Pacific ECMO Market Revenue and Forecast to 2028 (US$ Million)

 

Asia-Pacific ECMO Strategic Insights

Strategic insights for the Asia-Pacific ECMO provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia-Pacific ECMO Report Scope

Asia-Pacific ECMO Regional Insights

The geographic scope of the Asia-Pacific ECMO refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Asia-Pacific ECMO Market Segmentation

The Asia-Pacific ECMO market is segmented based on modality, application, age group, and country.    

Based on modality, the Asia-Pacific ECMO market is segmented into venoarterial ECMO, venovenous ECMO, and arteriovenous ECMO. The venoarterial ECMO segment held the largest market share in 2022.

Based on application, the Asia-Pacific ECMO market is bifurcated into respiratory and cardiology. The respiratory segment held a larger market share in 2022.

Based on age group, the Asia-Pacific ECMO market is segmented into adults, pediatrics, and neonates. The adults segment held the largest market share in 2022.

Based on country, the Asia-Pacific ECMO market has been categorized into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. Our regional analysis states that China dominated the market in 2022.        

ABIOMED Inc, Braile Biomedica, Eurosets S.R.L., Fresenius Medical Care AG & Co KGaA, Getinge AB, LivaNova Plc, Medtronic Plc, MicroPort Scientific Corporation, Nipro Medical Corporation, and Terumo Group are the leading companies operating in the Asia-Pacific ECMO market.